“Over the past months, Vincerx has completed transformative milestones; licensing a compelling oncology pipeline from Bayer, launching as a public company, and strengthening our already proven leadership team,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Since September 2010, Ms Bushnell has served as a member of the board of directors of the Legal Aid Society of San Mateo County. “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. “These accomplishments, in combination with our strong balance sheet, leave us well positioned as we … Sign up for the Good Day BIO Newsletter >. Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from February 2013 to February 2016. “The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Laura Bushnell, JD is a member of Vincerx’s board of directors. March 31, 2021. Employer Identification No.) We lead with respect, humanity, integrity, and inclusion. Ahmed Hamdy, MD Ceo 28 Number of Employees Company profile for Vincerx Pharma, including a description, list of executives, contact details and other key facts. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director: X: … Before that, Dr Lee served as senior vice president of clinical development of Nantkwest, Inc., an innovative clinical-stage immunotherapy company, from May 2016 to May 2020. He also served as a director of EpiBiome, Inc., a microbiome engineering company, from May 2016 to June 2018, and as a director and chairman of the audit committee for Asante Solutions, Inc., a medical device company, from December 2014 to October 2015. Mr Salva co-founded Acerta Pharma and served as its vice president of operations from February 2013 to November 2016. From January 2015 to December 2018, Mr Lowe served as chief financial officer of Sentreheart, Inc., a biotechnology company. "The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development," Hamdy said in a statement. Watch the Best of BIO Sessions. Vincera Pharma Contact if you may have any questions or want to speak to us. Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Association for Cancer Research Annual Meeting 2021 “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in a statement. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. Vincerx Pharma was founded by CEO Ahmed Hamdy, MD, COO Raquel Izumi, PhD, CBO Stuart Hwang, PhD, General Counsel, Tom Thomas and John Byrd, MD. PALO ALTO, Calif., April 01, 2021 -- Vincerx Pharma, Inc. , a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting... | April 30, 2021 Issuer Name and Ticker or Trading Symbol Vincera Pharma, Inc. [ VINC] 4. Bringing you daily news at the intersection of biotechnology, politics, patients & the planet. “The clearance of Vincerx’s first company-sponsored IND is an important milestone that paves the way for the initiation of our planned Phase 1b dose escalation study of VIP152 in patients with relapsed/refractory chronic lymphocytic leukemia and Richter syndrome in the second half of the year,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Dr Izumi began her research career at Amgen, where she held positions of increasing responsibility and participated in a successful BLA filing and approval for ARANESP®. Vincerx’s second clinical program for potential best-in-class CDK9 inhibitor . Health equality in access to medicines and ensuring diversity in clinical trials. Dr. Ahmed M. Hamdy, who previously also held the title of President, will continue as the Company’s Chief Executive Officer and Chairman of the Board and as the Company’s principal executive officer. Phase 1b studies in in Myc-driven hematologic malignancies and solid tumors, as well as relapsed/refractory Chronic Lymphocytic Leukemia to initiate in 1H 2021 PALO ALTO, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a … Before that, Mr Salva served as senior director of corporate finance at Pharmacyclics. Since May 2018, Dr Druker has served as a member of the board of directors of Amgen Inc., a multinational biopharmaceutical company. The only place for free North American stock rankings incorporating insider commitment. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board of directors since March 2019. Palo Alto, CA 94306 (650) 800-6676 (Name and address of agent for service) (650) 800-6676 (Registrant’s telephone number, including area code) Copies to: Gabriella A. Lombardi, Esq. “The Vincerx team is thrilled to welcome globally recognized key opinion leaders in hematologic malignancies and oncology drug development to our newly formed SAB,” said Ahmed Hamdy … Vincerx Pharma, Inc. 2020 Stock Incentive Plan (Full title of the plan) Ahmed M. Hamdy. BIO now offers on-demand online classes that can be taken anywhere, anytime and at your own pace. Biotech SPACs (special purpose acquisition companies) have reached record levels in 2020. Vote “Underperform” if you believe VINC will underperform the S&P 500 … PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the formation of its Scientific Advisory Board (SAB) composed of world leading academics and industry leaders in cancer research and … Dr Lee served as executive director of the Chan Soon Shiong Institute of Molecular Medicine, a biomedical and translational research institute and as a full professor at the University of South Dakota, from May 2016 to September 2018 and September 2010 to May 2016, respectively. Christopher Lowe, MBA is a member of Vincerx’s board of directors. Top market players in the market are Airbus S.A.S., Amazon.com, Inc., BIZZBY, Boeing, Cheetah Logistic Technology, Deutsche Post … Dr Izumi was a Howard Hughes Predoctoral Fellow at the University of California, Los Angeles where she obtained a PhD in microbiology and immunology. Francisco D. Salva is a member of Vincerx’s board of directors. Chief Executive Officer. The market is expected to surge at a CAGR of 53% and is anticipated to surpass USD 6,773 Million by 2026. MarketBeat's community ratings are surveys of what our community members think about Vincerx Pharma and other stocks. “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in a … Limerick and Clare Education and … Ahmed M. Hamdy, M.D. PALO ALTO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced the completion of its redemption event with respect to … “The payload is a modified camptothecin derivative which has been optimized for high cell … That trial is expected to begin dosing patients in Q2 of 2021, said Vincerx CEO Ahmed Hamdy. Dr Lee has served as chief medical officer of cancer research of Avera Health, a regional healthcare system, since May 2020 and as chief medical officer of ImmunityBio, Inc., a registration stage immuno-oncology and infectious disease company, since March 2019. “The addition of Hermes, Hans-Georg, and Tom to the Vincerx team provides important expertise and experience to our accomplished management team as we enter the next stage of our development,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. "These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through ? Current assets: Cash and cash equivalents Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in … Cookies are used to offer you a better browsing experience and to analyze our traffic. Dr Izumi has served as Vincerx’s Chief Operations Officer and as a member Vincerx’s board of directors since March 2019. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board … From 2004 to 2006, Dr McDonald served as head of healthcare research and a biotechnology analyst at ThinkEquity Partners, a boutique investment bank. Employer Identification No.) Mr Lowe holds a BS in business administration from California Polytechnic State University and an MBA from St. Mary’s University, Texas. Hamdy Ahmed MD (Last) (First) (Middle) 4500 GREAT AMERICA PARKWAY, SUITE 100, #29 (Street) SANTA CLARA: CA: 95054 (City) (State) (Zip) 2. Dr Druker has served in various capacities at the Oregon Health and Science University, as a physician since July 1993, professor since July 2000, and associate dean of Oncology since July 2010. “The IND clearance for VIP152 in CLL is an important milestone for Vincerx, marking our first IND clearance and now second clinical program for what we believe is the most selective CDK9 inhibitor in clinical development,” said Ahmed Hamdy M.D., Chief Executive Officer of Vincerx. Raquel Izumi, PhD is the Chief Operations Officer and President of Vincerx and a member of the Vincerx board of directors. Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Dr Stevens was a Recipient of 2019 Oregon State University, Icon of Pharmacy award, and induction into the Pharmacy Hall of Fame. That trial is expected to begin dosing patients in Q2 of 2021, said Vincerx CEO Ahmed Hamdy. Partner Content Back to Top Dr Hamdy received a MBBCH from the KasrAlainy School of Medicine at the University of Cairo, Egypt. Get stock quotes, news, fundamentals and easy to read SEC and SEDI insider filings. Mr Lowe served as a director for Inspyr Therapeutics, Inc., an integrated biopharmaceutical company, from September 2016 to December 2018. “Preclinical data for VIP152 show highly selective, ATP-independent, inhibition of … Dr Izumi also co-founded Aspire Therapeutics LLC and served as its chief scientific officer from June 2011 to February 2013. Dr McDonald has served as chief executive officer of Attune Pharmaceuticals, a clinical-stage biotechnology company, since March 2015 and is a founding partner of LifeSci Advisors, LLC, a life sciences investor relations consultancy company, and LifeSci Capital, LLC, an emerging life sciences investment bank. In the current and next generation of black scientists and entrepreneurs. Vincerx Pharma, Inc. Condensed Consolidated Balance Sheets. “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. Vincerx Pharma Inc. (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to … Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Dr Lee served as director of the cancer center of Stanford Health, a leading academic health system from July 2012 to May 2016. “We are particularly focused on har-nessing our versatile toolbox of innovative link-ers, payloads and bioconjugation chemistries to advance the next generation of small molecule and antibody–drug conjugates with potential for making significant inroads into the fight against some of the more intractable forms of cancer.” Vincerx … Mr Lowe also served as the Managing Partner of the Innventus Fund at Innventure, a venture capital firm, from January 2017 to March 2020 and as a member of the board of directors of Innventure from August 2016 to January 2020. File Number) (I.R.S. Andrew McDonald, PhD is a member of Vincerx’s board of directors. Dr Stevens was a founder and has served as Chief Scientific Officer and Executive Vice President of Camargo Pharmaceutical Services, LLC, a drug development consulting company, since 2003, and a member of its board of directors since March 2017. of Incorporation) (Commission. Ruth Stevens, PhD, MBA is a member of Vincerx’s board of directors. Dr Stevens is an adjunct professor at the University of Cincinnati, College of Pharmacy, since March 1997. She received honors and distinction for her BA in biological sciences from the University of California, Santa Barbara. of Incorporation) (Commission. Before founding LifeSci Advisors, LLC, and LifeSci Capital, LLC, in March 2010, Dr McDonald served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008. Before that, Dr Izumi co-founded Acerta Pharma and served as its executive vice president of clinical development from February 2013 to May 2020. “Vincerx is a young company poised to deliver paradigm-shifting therapeutics to address the unmet medical needs of cancer patients world-wide,” said Ahmed Hamdy, CEO and cofounder of Vincerx. Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker," said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. 260 Sheridan Avenue, Suite 400 : Palo Alto, California : 94306 (Address of principal executive offices) (Zip Code) (650) 800-6676 (Registrant’s … Home of the insider insights newsletter and the Canadian Insider Club which offers alerts and premium research. A recent…, 1201 Maryland Avenue SW, Suite 900, Washington, DC, 20024 ・ 202-962-9200. New extended dates for the world’s largest biotech partnering experience, October 19-20, 2021 Dr Druker has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences. Dr Lee served as a member of the board of directors of Windber Hospital from June 2018 to May 2020. “This group’s combined decades of medical, scientific and legal acumen across biotech will be key as we work towards advancing our pipeline of targeted oncology therapeutics,” Vincerx CEO Ahmed Hamdy said in a statement. “These preclinical data demonstrate that VIP236 has enhanced tumor specificity via tumor specific binding through α v β 3 integrin and targeted drug release in the TME with our neutrophil elastase cleavable linker,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx. Ms Bushnell has served as a member of the board of trustees of the University of California, Santa Cruz, Foundation since February 2015, and as chair of the Dean’s Council of the Baskin School of Engineering at the University of California, Santa Cruz, since July 2019. Dr Hamdy has served as a clinical advisor and member of the board of directors of Andes Biotechnologies, a nucleic acid-based drug discovery and development company, since September 2016, as a member of the Dean’s Council of the Jack Baskin School of Engineering at the University of California, Santa Cruz, since April 2019, and as a member of the Palo Alto Medical Foundation President’s Council since March 2016. Mr Salva received an AB in business economics and an AB in philosophy from Brown University and a MSc in economics and philosophy form the London School of Economics. “These accomplishments, in combination with our strong balance sheet, leave us well …
Think Like A Citizen Scientist Journey Brownie, Ipswich Town Premier League Record, Peter Clarke Actor, Croydon Best Start Contact Number, Bloom Hulk Mtg Explained, Affirm Office Address, Brooklyn Nets Fans Reddit, Lancôme Face Cream Set, Herbivores Animals List,